Medincell SA MEDCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MEDCL is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €15.40
- Day Range
- €14.72–15.66
- 52-Week Range
- €5.25–17.50
- Bid/Ask
- €14.84 / €15.00
- Market Cap
- €432.89 Mil
- Volume/Avg
- 166,941 / 85,508
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 36.14
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 138
- Website
- https://www.medincell.com
Comparables
Valuation
|
Metric
|
MEDCL
|
AELIS
|
ALFRE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 14.12 |
Price/Book Value | — | 12.98 | 1.22 |
Price/Sales | 36.14 | 18.52 | 0.22 |
Price/Cash Flow | — | — | 8.60 |
Price/Earnings
MEDCL
AELIS
ALFRE
Financial Strength
|
Metric
|
MEDCL
|
AELIS
|
ALFRE
|
|---|---|---|---|
Quick Ratio | 1.91 | 2.38 | 1.31 |
Current Ratio | 1.99 | 2.48 | 1.33 |
Interest Coverage | −4.87 | −33.55 | 6.88 |
Quick Ratio
MEDCL
AELIS
ALFRE
Profitability
|
Metric
|
MEDCL
|
AELIS
|
ALFRE
|
|---|---|---|---|
Return on Assets (Normalized) | −63.12% | −14.59% | 4.03% |
Return on Equity (Normalized) | — | −28.94% | 13.43% |
Return on Invested Capital (Normalized) | −76.45% | −24.22% | 8.50% |
Return on Assets
MEDCL
AELIS
ALFRE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rylplgrbvk | Wpj | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dbnjlych | Nsqtpmx | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ngbrsqrz | Nvggqs | $105.3 Bil | |
MRNA
| Moderna Inc | Mtvxxlyjg | Rxll | $47.0 Bil | |
ARGX
| argenx SE ADR | Yjtcrtkt | Kgszb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cfywjpm | Krbz | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sjqykyslv | Wxnsrx | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vdmknkts | Wjncxrb | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dnqrtvdgk | Mwxnlbr | $12.7 Bil | |
INCY
| Incyte Corp | Zvwjlhjp | Lfjdds | $12.0 Bil |